Furthermore, the authors argue the important role of PSMA-targeted radiopharmaceuticals in the management of giant cell tumor of bone by demonstrating PSMA-specific fluorescent probe (FAM-C6-1298) uptake in PSMA positive cells, indicating successful targeting of these tumors in vitro [31]. This evidence concerns the gene FOLH1 and giant cell tumor.